What you missed in June: More on Harvard research lab, Sarepta Therapeutics, and UnitedHealth

Get 25% off an annual STAT+ subscription and read more of our award-winning journalism.

My Account    STAT+ Check out last month's top stories. If you like what you see, join the STAT+ community today – and enjoy 25% off your first year with code LOYAL25. STAT/Jenn Ackerman for STAT 1   Internal document shows how UnitedHealth executives prepared to tamp down investor unrest By Casey Ross, Tara Bannow, and Bob Herman Photo illustration: Christine Kao/STAT; Photos: Alex Brandon/AP 2   The shrewd startup founder who led DOGE's cost-cutting at HHS By Tara Bannow Kent Dayton/Harvard T.H. Chan School of Public Health 3   Private equity firm will finance Harvard research lab, in possible template for future By Allison DeAngelis 25% off STAT+ Get 25% off your first year of STAT+ with discount code LOYAL25. SUBSCRIBE NOW More Top Stories 4   Disagreements over Duchenne therapy, management style may have led to ouster of key FDA official By Adam Feuerstein, Matthew Herper, Jason Mast, and Lizzy Lawrence 5   Cogent Biosciences-Blueprint Medicines tiff turns spicy on eve of immune drug study readout By Adam Feuerstein 6   Top gene therapy regulator forced out at FDA By Jason Mast and Adam Feuerstein 7   Insmed is an attractive, but expensive takeout meal By Adam Feuerstein 8   After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry By Adam Feuerstein and Jason Mast 9   What's next for Sarepta Therapeutics with gene therapy under fire? By Adam Feuerstein 10   In fight over research overhead funding, universities propose alternatives to Trump's cuts By Jonathan Wosen read more STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails Update Newsletter Preferences • Contact Us • Advertise with Us